ACADIA PHARMACEUTICALS INC (ACAD) Fundamental Analysis & Valuation

NASDAQ:ACAD • US0042251084

22.58 USD
+0.42 (+1.9%)
At close: Mar 9, 2026
22.58 USD
0 (0%)
After Hours: 3/9/2026, 5:32:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ACAD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ACAD. ACAD was compared to 519 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. ACAD Profitability Analysis

1.1 Basic Checks

  • ACAD had positive earnings in the past year.
  • In the past year ACAD had a positive cash flow from operations.
  • ACAD had negative earnings in 4 of the past 5 years.
  • In the past 5 years ACAD reported 4 times negative operating cash flow.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 25.00%, ACAD belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 31.86%, ACAD belongs to the top of the industry, outperforming 97.11% of the companies in the same industry.
  • ACAD's Return On Invested Capital of 6.43% is amongst the best of the industry. ACAD outperforms 91.33% of its industry peers.
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROIC 6.43%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 36.49%, ACAD belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ACAD has declined.
  • ACAD's Operating Margin of 9.78% is amongst the best of the industry. ACAD outperforms 90.37% of its industry peers.
  • In the last couple of years the Operating Margin of ACAD has declined.
  • Looking at the Gross Margin, with a value of 91.69%, ACAD belongs to the top of the industry, outperforming 92.87% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
Industry RankSector Rank
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ACAD Health Analysis

2.1 Basic Checks

  • ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ACAD has been reduced compared to 1 year ago.
  • Compared to 5 years ago, ACAD has more shares outstanding
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • ACAD has an Altman-Z score of 6.62. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ACAD (6.62) is better than 75.53% of its industry peers.
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.62
ROIC/WACC0.73
WACC8.79%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 3.83 indicates that ACAD has no problem at all paying its short term obligations.
  • ACAD has a Current ratio (3.83) which is in line with its industry peers.
  • A Quick Ratio of 3.71 indicates that ACAD has no problem at all paying its short term obligations.
  • The Quick ratio of ACAD (3.71) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.71
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ACAD Growth Analysis

3.1 Past

  • ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 377.08%, which is quite impressive.
  • Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 113.98%.
  • ACAD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%

3.2 Future

  • Based on estimates for the next years, ACAD will show a small growth in Earnings Per Share. The EPS will grow by 6.61% on average per year.
  • The Revenue is expected to grow by 11.19% on average over the next years. This is quite good.
EPS Next Y-77.91%
EPS Next 2Y-34.06%
EPS Next 3Y-8.28%
EPS Next 5Y6.61%
Revenue Next Year15.25%
Revenue Next 2Y13.28%
Revenue Next 3Y13.33%
Revenue Next 5Y11.19%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. ACAD Valuation Analysis

4.1 Price/Earnings Ratio

  • ACAD is valuated reasonably with a Price/Earnings ratio of 9.86.
  • Based on the Price/Earnings ratio, ACAD is valued cheaper than 97.69% of the companies in the same industry.
  • ACAD is valuated cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 44.64 indicates a quite expensive valuation of ACAD.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 90.94% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, ACAD is valued quite expensively.
Industry RankSector Rank
PE 9.86
Fwd PE 44.64
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • ACAD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ACAD is cheaper than 94.80% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 89.79% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 610.28
EV/EBITDA 14.36
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of ACAD may justify a higher PE ratio.
  • A cheap valuation may be justified as ACAD's earnings are expected to decrease with -8.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.06%
EPS Next 3Y-8.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACAD Dividend Analysis

5.1 Amount

  • ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACAD Fundamentals: All Metrics, Ratios and Statistics

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (3/9/2026, 5:32:47 PM)

After market: 22.58 0 (0%)

22.58

+0.42 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners98.63%
Inst Owner Change-2.51%
Ins Owners0.26%
Ins Owner Change-0.95%
Market Cap3.85B
Revenue(TTM)1.07B
Net Income(TTM)391.00M
Analysts78.52
Price Target32.16 (42.43%)
Short Float %5.29%
Short Ratio5.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)611.18%
Min EPS beat(2)178.22%
Max EPS beat(2)1044.15%
EPS beat(4)3
Avg EPS beat(4)308.41%
Min EPS beat(4)-3.19%
Max EPS beat(4)1044.15%
EPS beat(8)6
Avg EPS beat(8)160.73%
EPS beat(12)8
Avg EPS beat(12)114.4%
EPS beat(16)11
Avg EPS beat(16)90.18%
Revenue beat(2)0
Avg Revenue beat(2)-3.01%
Min Revenue beat(2)-4.84%
Max Revenue beat(2)-1.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-4.84%
Max Revenue beat(4)0.08%
Revenue beat(8)2
Avg Revenue beat(8)-2.38%
Revenue beat(12)5
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)1.35%
PT rev (3m)7.73%
EPS NQ rev (1m)-37.19%
EPS NQ rev (3m)-33.37%
EPS NY rev (1m)-33.88%
EPS NY rev (3m)-38.11%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)3.5%
Revenue NY rev (3m)3.34%
Valuation
Industry RankSector Rank
PE 9.86
Fwd PE 44.64
P/S 3.59
P/FCF 610.28
P/OCF 35.05
P/B 3.14
P/tB 3.44
EV/EBITDA 14.36
EPS(TTM)2.29
EY10.14%
EPS(NY)0.51
Fwd EY2.24%
FCF(TTM)0.04
FCFY0.16%
OCF(TTM)0.64
OCFY2.85%
SpS6.28
BVpS7.2
TBVpS6.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.26
Profitability
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROCE 8.14%
ROIC 6.43%
ROICexc N/A
ROICexgc N/A
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
FCFM 0.59%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 880.34%
Cap/Sales 9.66%
Interest Coverage 250
Cash Conversion 94.22%
Profit Quality 1.61%
Current Ratio 3.83
Quick Ratio 3.71
Altman-Z 6.62
F-Score3
WACC8.79%
ROIC/WACC0.73
Cap/Depr(3y)535%
Cap/Depr(5y)327.69%
Cap/Sales(3y)570.92%
Cap/Sales(5y)342.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
EPS Next Y-77.91%
EPS Next 2Y-34.06%
EPS Next 3Y-8.28%
EPS Next 5Y6.61%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%
Revenue Next Year15.25%
Revenue Next 2Y13.28%
Revenue Next 3Y13.33%
Revenue Next 5Y11.19%
EBIT growth 1Y201.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.22%
EBIT Next 3Y55.06%
EBIT Next 5Y44.44%
FCF growth 1Y549.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7923.08%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.


Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?

The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 9.86 and the Price/Book (PB) ratio is 3.14.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 8 / 10.